DOCSLIB.ORG

14-350 Phrma Cancer2014 1001.Indd

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
14-350 Phrma Cancer2014 1001.Indd 2014 MEDICINES IN DEVELOPMENT REPORT Cancer PRESENTED BY AMERICA’S BIOPHARMACEUTICAL RESEARCH COMPANIES Nearly 800 Medicines and Vaccines in Clinical Testing For Cancer Offer New Hope to Patients In recent decades, great progress has America’s biopharmaceutical companies Medicines in Development for been made in the fi ght against cancer. are responding to the needs of cancer Cancer Advances in molecular and genomic patients, working to develop more and research have unveiled complexities better treatments. Researchers are now Application Submitted and changed the perception of cancer, exploring new high-tech weapons to Phase III which we now know is more than 200 fi ght the disease as well as ways to use Phase II unique diseases. Continued research existing medicines, either alone or in has expanded our knowledge of how combination with other therapies, to Phase I cancer develops and how to target treat various cancers. The 771 medicines 98 medicines for specifi c cancer types, and vaccines are either in clinical trials which has resulted in more effective or awaiting review by the U.S. Food and therapies for patients. Drug Administration (FDA) and include: 87 A cancer diagnosis once meant almost • A monoclonal antibody for colorectal 78 certain death but with new therapies, cancer that targets a cell surface 73 better testing, earlier diagnosis and protein that plays a role in tumor follow-up care, patients are often able growth and metastases; to live longer with a better quality of life. According to the American Cancer 56 Contents Society (ACS), the number of cancer Medicines and Vaccines in 48 survivors living in the United States has Development to Treat Cancer ...............2 increased from 3 million in 1971 to 13.7 Advances in Cancer Treatment .............3 million in 2012. Value in Cancer Care Although great progress has been made in the United States ............................5 and continues to be made against Research Collaboration: Public-Private Partnerships ...................................... 6 cancer, it remains the second leading Facts About Cancer in the cause of death in the United States, United States .................................... 8 behind heart disease, accounting Medicines and Vaccines in for nearly 1 of every 4 deaths. The Development Chart ........................... 12 ACS estimates that in 2014, more The Drug Discovery, Development than 1.6 million new cancer cases will and Approval Process ...................... 103 ast er er er er e emia Skin be diagnosed and nearly 600,000 Lunganc arian anc Br C C euk Ov Canc Americans will die from cancer, Canc L ymphoma L approximately 1,600 people per day. Some medicines are listed in more than one category. Key Issues • A monoclonal antibody for non-small-cell lung cancer that blocks a signaling pathway allowing for immune responses that can recognize and destroy cancer cells; • A medicine that targets and disrupts a signaling pathway associated with tumor growth in stomach cancer. The development of new therapies would not be possible without the patients who volunteer to participate in clinical trials. Currently, there are 3,137 active clinical trials for cancer in the United States. Of those, 1,824 are now seeking volunteers to participate or have not yet started recruiting patients; the other 1,313 are ongoing but are not currently recruiting new patients.* The progress made against cancer has resulted in better treatments that help extend lives, improve patients’ quality of life, and increase productivity contributing to economic growth. The hundreds of medicines being developed are our best hope for continuing that progress and lessening the burden of cancer. However, researching and developing new medicines remains a risky investment and a lengthy process. On average, it costs $1.2 billion and takes between 10–15 Medicines and Vaccines in years to bring a new, effective medicine to patients. Despite Development to Treat Cancer those risks, America’s biopharmaceutical research companies are continuing their efforts to develop effective new therapies Many of the medicines in the pipeline today are using for the prevention and treatment of cancer. novel approaches to attack cancer at the molecular level. Approximately 80 percent of cancer pipeline drugs are potentially fi rst-in-class treatments, according to the Tufts Center for the Study of Drug Development. Among the 771 medicines and vaccines in development are potential treatments for: Colorectal Cancer—A humanized monoclonal antibody in development for metastatic colorectal cancer targets the cell surface protein “endosialin,” which is expressed on cells that are part of the tumor blood vessel structure. In preclinical studies, blocking the function of endosialin inhibited tumor growth and metastases. Liver Cancer—A medicine in development for hepatocellular carcinoma (liver cancer) is a small molecule kinase inhibitor designed to selectively block transforming growth factor-beta (TGF-beta) signaling. The overexpression of TGF-beta in cells may enhance tumor growth and intensify metastases. *Source: www.clinicaltrials.gov, search performed 9/25/2014. Search criteria: cancer, United States, Phase 0, 1, 2, 3; industry only; excluding unknown status. 2 Medicines in Development Cancer 2014 Key Issues Lung Cancer—A fully human monoclonal antibody in thought to play a role in tumor growth and metastases in development for non-small-cell lung cancer targets the many cancers, including stomach cancer. An exploratory PD-1 (programmed death-1) checkpoint receptor which is biomarker analysis found that the addition of the medicine to expressed on activated T-cells. Cancer cells may exploit chemotherapy improved median overall survival in patients the checkpoint pathway to hide from the immune system with tumors that expressed high levels of MET protein. and protect the tumor. Blocking this pathway may allow for immune responses that recognize and destroy cancer cells. Another medicine which blocks the PD-1 receptor was “ ere is no question that when we talk recently approved by FDA for the treatment of malignant melanoma. about turning the tide against cancer, the most exciting opportunities, Pancreatic Cancer—In malignant solid tumors, oxygen levels are often low (called tumor hypoxia) relative to oxygen levels the new opportunities in fact, are in healthy tissue. Tumor hypoxia is associated with tumor understanding the biology and progression, metastases, and resistance to chemotherapy applying that biology to new treatments. and radiation treatment. A medicine in development is We are certainly at a turning point.” activated when it reaches the hypoxic region of the tumor environment where it eventually kills tumor cells in its vicinity. —J. Leonard Lichtenfeld, M.D., American Cancer Society The medicine is also being tested in patients with soft tissue sarcoma. Stomach Cancer—A monoclonal antibody in testing for Advances in Cancer Treatment stomach cancer with high MET (mesenchymal-epithelial As we continue to advance cancer treatment, progress can transition factor) expression is designed to inhibit hepatocyte be seen in declining death rates from cancer and increases in growth factor (HGF)/scatter factor from binding to the cancer survivors. According to the ACS, the death rate from c-MET receptor. The HGF/c-Met signaling pathway is cancer has been steadily declining since the 1970s—declining more than 15 percent in the period from 2000-2011 alone. Five-year survival rates have increased 39 percent across all cancer types since 1975, with 2 out of 3 people diagnosed with cancer surviving at least fi ve years. To sustain this progress in an environment of increasing pressure to contain health care costs, it is important to understand the valuable role new medicines play in improving patient outcomes. According to the ACS, 83 percent of survival gains are attributable to new treatments, including medicines. Some key advances in treatment include: Personalized Medicines—Personalized medicines are therapeutics that are tailored to individual patients based on certain biologic and physiologic characteristics, such as genetic makeup. Patients can be identifi ed by their susceptibility to a certain disease or how they will likely respond to a specifi c therapy. By targeting therapies to patients most likely to benefi t, personalized medicines represent an important tool, as they may reduce the use of Medicines in Development Cancer 2014 3 Key Issues Targeted Therapies—Targeted therapies are designed to HOW CANCER COULD ECHO interfere with specifi c molecular targets involved in cancer cell growth or progression, whereas traditional chemotherapy HIV SUCCESS acts against all rapidly dividing cells, including healthy ones. Innovations in cancer treatment could echo the Several targeted therapies have been approved for use by success we have seen in HIV/AIDS treatment. the FDA. According to IMS Health, the role of targeted therapies in oncology treatment has grown from 11 percent in Advances in medicines for HIV/AIDS have 2003 to 46 percent in 2013. helped lower the death rate by 83 percent since the disease was fi rst recognized in 1981. Prior to Therapeutic Cancer Vaccines—In the late 1990s, scientists began experimenting with new vaccines that could harness 1995, when the fi rst antiretroviral medicine was the power of the immune system to fi ght cancer rather approved by the FDA, an HIV diagnosis was than to prevent it. One type of therapeutic vaccine, called a death sentence. Now, thanks to medicines
Load more

Recommended publications
  • ( 12 ) Patent Application Publication ( 10 ) Pub . No .: US 2020/0121788 A1
    US 20200121788A1 IN (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No .: US 2020/0121788 A1 MASSIMINI et al. (43 ) Pub . Date : Apr. 23 , 2020 ( 54 ) ABITUZUMAB FOR THE TREATMENT OF A61K 31/44 (2006.01 ) COLORECTAL CANCER A61P 35/00 (2006.01 ) (52 ) U.S. Cl. ( 71) Applicant: Merck Patent GmbH , Darmstadt (DE ) CPC ... A61K 39/39558 (2013.01 ) ; CO7K 16/2848 ( 2013.01 ) ; CO7K 16/2863 ( 2013.01 ) ; CO7K ( 72 ) Inventors: Giorgio MASSIMINI, Darmstadt (DE ) ; 16/22 (2013.01 ) ; A61K 31/4745 ( 2013.01 ) ; Ilhan Celik , Zwingenberg (DE ) ; Josef A61K 31/513 ( 2013.01 ) ; A61K 2039/505 Straub , Seeheim - Jugenheim (DE ) ; Rolf ( 2013.01) ; A61K 31/519 ( 2013.01 ) ; A61K Bruns, Darmstadt ( DE ) 33/243 (2019.01 ) ; A6IK 38/179 ( 2013.01) ; A61K 31/44 ( 2013.01) ; A61P 35/00 ( 2018.01 ) ; ( 73 ) Assignee: Merck Patent GmbH , Darmstadt (DE ) CO7K 2317/76 ( 2013.01) ; A61K 31/7072 ( 21 ) Appl. No .: 16 /657,828 ( 2013.01) ( 22 ) Filed : Oct. 18 , 2019 (57 ) ABSTRACT Methods of treatment of colorectal cancer can include the Related U.S. Application Data administration of the anti - alpha - v integrin (receptor ) anti (60 ) Provisional application No. 62 / 748,114 , filed on Oct. body Abituzumab . Preferably , the methods of treating col 19 , 2018 . orectal cancer can include treating Stage II - IV colorectal cancer, metastatic colorectal cancer , left - sided colorectal Publication Classification cancer and /or left- sided metastatic colorectal cancer, involv ( 51) Int. Ci. ing the administration of said Abituzumab to patients in need A61K 39/395 ( 2006.01 ) thereof. Abituzumab is also useful for the manufacture of a COZK 16/28 ( 2006.01 ) medicament for treating colorectal cancer , preferably col COOK 16/22 ( 2006.01 ) orectal cancer as defined herein .
    [Show full text]
  • Precision Medicine for Human Cancers with Notch Signaling Dysregulation (Review)
    INTERNATIONAL JOURNAL OF MOleCular meDICine 45: 279-297, 2020 Precision medicine for human cancers with Notch signaling dysregulation (Review) MASUKO KATOH1 and MASARU KATOH2 1M & M PrecMed, Tokyo 113-0033; 2Department of Omics Network, National Cancer Center, Tokyo 104-0045, Japan Received September 16, 2019; Accepted November 20, 2019 DOI: 10.3892/ijmm.2019.4418 Abstract. NOTCH1, NOTCH2, NOTCH3 and NOTCH4 are conjugate (ADC) Rova-T, and DLL3-targeting chimeric antigen transmembrane receptors that transduce juxtacrine signals of receptor‑modified T cells (CAR‑Ts), AMG 119, are promising the delta-like canonical Notch ligand (DLL)1, DLL3, DLL4, anti-cancer therapeutics, as are other ADCs or CAR-Ts targeting jagged canonical Notch ligand (JAG)1 and JAG2. Canonical tumor necrosis factor receptor superfamily member 17, Notch signaling activates the transcription of BMI1 proto-onco- CD19, CD22, CD30, CD79B, CD205, Claudin 18.2, fibro- gene polycomb ring finger, cyclin D1, CD44, cyclin dependent blast growth factor receptor (FGFR)2, FGFR3, receptor-type kinase inhibitor 1A, hes family bHLH transcription factor 1, tyrosine-protein kinase FLT3, HER2, hepatocyte growth factor hes related family bHLH transcription factor with YRPW receptor, NECTIN4, inactive tyrosine-protein kinase 7, inac- motif 1, MYC, NOTCH3, RE1 silencing transcription factor and tive tyrosine-protein kinase transmembrane receptor ROR1 transcription factor 7 in a cellular context-dependent manner, and tumor-associated calcium signal transducer 2. ADCs and while non-canonical Notch signaling activates NF-κB and Rac CAR-Ts could alter the therapeutic framework for refractory family small GTPase 1. Notch signaling is aberrantly activated cancers, especially diffuse-type gastric cancer, ovarian cancer in breast cancer, non-small-cell lung cancer and hematological and pancreatic cancer with peritoneal dissemination.
    [Show full text]
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Immune Regulation by CD52-Expressing CD4 T Cells
    Cellular & Molecular Immunology (2013) 10, 379–382 ß 2013 CSI and USTC. All rights reserved 1672-7681/13 $32.00 www.nature.com/cmi RESEARCH HIGHLIGHT Immune regulation by CD52-expressing CD4 T cells Ban-Hock Toh1, Tin Kyaw1,2, Peter Tipping1 and Alex Bobik2 T-cell regulation by CD52-expressing CD4 T cells appears to operate by two different and possibly synergistic mechanisms. The first is by its release from the cell surface of CD4 T cells that express high levels of CD52 that then binds to the inhibitory sialic acid-binding immunoglobulin-like lectins-10 (Siglec-10) receptor to attenuate effector T-cell activation by impairing phosphorylation of T-cell receptor associated lck and zap-70. The second mechanism appears to be by crosslinkage of the CD52 molecules by an as yet unidentified endogenous ligand that is mimicked by a bivalent anti-CD52 antibody that results in their expansion. Cellular & Molecular Immunology (2013) 10, 379–382; doi:10.1038/cmi.2013.35; published online 12 August 2013 he immune system is designed to appears in the affirmative, and includes suppression was lost by cleavage of N- T protect its host from invading players such as IL-10-secreting Tr1 and glycans from CD52-Fc by peptide N- pathogens and yet remain non-reactive TGF-b-secreting Th3. cells. Absence of glycosidase or by removal of sialic acid to self. Immunological homeostasis is surface markers limited the usefulness residues by neuraminidase. Suppression maintained by purging self-reactive lym- of these other regulators. However, the was also blocked by antibody to the phocytes by clonal deletion coupled with recent report that CD49b and lympho- extracellular domain of Siglec-10 and a regulatory population of lymphocytes cyte activation gene-3 are highly and sta- by soluble Siglec-10-Fc.
    [Show full text]
  • Andrew Lai Thesis
    TOWARDS THE DEVELOPMENT OF NOVEL BISPECIFIC ANTIBODIES TO INHIBIT KEY CELL SURFACE RECEPTORS INTEGRAL FOR THE GROWTH AND MIGRATION OF TUMOUR CELLS Andrew Lai Bachelor of Science, UNSW 2008 Master of Biotechnology, QUT 2010 Bachelor of Applied Science (Hons), QUT 2012 Submitted for the degree of Doctor of Philosophy Institute of Health and Biomedical Innovation Faculty of Health Queensland University of Technology 2016 Keywords Breast cancer, extracellular matrix, insulin-like growth factor, metastasis, migration, therapeutics, phage display, single chain variable fragments, vitronectin Towards the development of novel bispecific antibodies to inhibit key cell surface receptors integral for the growth and migration of tumour cells i Abstract Metastatic breast cancer, or breast cancer which has spread from the primary tumour to distal secondary sites, remains a major killer of women today. Researchers have observed that the relationship between tumour cells and its surrounding environment plays an important role in cancer progression. One such interaction is between the Insulin-like growth factor (IGF) system and the integrin system, which has been demonstrated to be involved in cancer cell metabolic activity and migration. Therefore, the aim of this project was to translate this knowledge into the generation of bispecific antibody fragments (BsAb) targeting both systems, in order to disrupt their roles in cancer growth and metastasis. To screen for IGF-1R and αv integrin binding ScFv, a phage display enrichment procedure using the Tomlinson ScFv libraries was conducted. After the panning cycles, 192 clones were screened for binding using ELISA, of which 16 were selected for sequencing. Analysis of the results revealed 1 IGF-R and 3 αv integrin unique binding ScFv, which were all subsequently expressed in a bacterial expression system.
    [Show full text]
  • Form 10-Q Regeneron Pharmaceuticals, Inc
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES (X) EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2013 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ( ) EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number 0-19034 REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 13-3444607 (State or other jurisdiction of (I.R.S. Employer Identification No.) incorporation or organization) 777 Old Saw Mill River Road, Tarrytown, New York 10591-6707 (Address of principal executive offices) (Zip Code) (914) 847-7000 (Registrant’s telephone number, including area code) Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes X No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.
    [Show full text]
  • USAN Naming Guidelines for Monoclonal Antibodies |
    Monoclonal Antibodies In October 2008, the International Nonproprietary Name (INN) Working Group Meeting on Nomenclature for Monoclonal Antibodies (mAb) met to review and streamline the monoclonal antibody nomenclature scheme. Based on the group's recommendations and further discussions, the INN Experts published changes to the monoclonal antibody nomenclature scheme. In 2011, the INN Experts published an updated "International Nonproprietary Names (INN) for Biological and Biotechnological Substances—A Review" (PDF) with revisions to the monoclonal antibody nomenclature scheme language. The USAN Council has modified its own scheme to facilitate international harmonization. This page outlines the updated scheme and supersedes previous schemes. It also explains policies regarding post-translational modifications and the use of 2-word names. The council has no plans to retroactively change names already coined. They believe that changing names of monoclonal antibodies would confuse physicians, other health care professionals and patients. Manufacturers should be aware that nomenclature practices are continually evolving. Consequently, further updates may occur any time the council believes changes are necessary. Changes to the monoclonal antibody nomenclature scheme, however, should be carefully considered and implemented only when necessary. Elements of a Name The suffix "-mab" is used for monoclonal antibodies, antibody fragments and radiolabeled antibodies. For polyclonal mixtures of antibodies, "-pab" is used. The -pab suffix applies to polyclonal pools of recombinant monoclonal antibodies, as opposed to polyclonal antibody preparations isolated from blood. It differentiates polyclonal antibodies from individual monoclonal antibodies named with -mab. Sequence of Stems and Infixes The order for combining the key elements of a monoclonal antibody name is as follows: 1.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
    bioRxiv preprint doi: https://doi.org/10.1101/572958; this version posted March 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Title: Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories. Authors: Konrad Krawczyk1*, Matthew Raybould2, Aleksandr Kovaltsuk2, Charlotte M. Deane2 1 NaturalAntibody, Hamburg, Germany 2 Oxford University Department of Statistics, Oxford, UK *Correspondence to [email protected] Abstract: Recently it has become possible to query the great diversity of natural antibody repertoires using Next Generation Sequencing (NGS). These methods are capable of producing millions of sequences in a single experiment. Here we compare Clinical Stage Therapeutic antibodies to the ~1b sequences from 60 independent sequencing studies in the Observed Antibody Space Database. Of the 242 post Phase I antibodies, we find 16 with sequence identity matches of 95% or better for both heavy and light chains. There are also 54 perfect matches to therapeutic CDR-H3 regions in the NGS outputs, suggesting a nontrivial amount of convergence between naturally observed sequences and those developed artificially. This has potential implications for both the discovery of antibody therapeutics and the legal protection of commercial antibodies. Introduction Antibodies are proteins in jawed vertebrates that recognize noxious molecules (antigens) for elimination. An organism expresses millions of diverse antibodies to increase the chances that some of them will be able to bind the foreign antigen, initiating the adaptive immune response.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 6,120,766 Hale Et Al
    USOO612O766A United States Patent (19) 11 Patent Number: 6,120,766 Hale et al. (45) Date of Patent: Sep.19, 2000 54) CDW52-SPECIFIC ANTIBODY FOR 56) References Cited TREATMENT OF MULTIPLE SCLEROSIS U.S. PATENT DOCUMENTS 76 Inventors: Geoffrey Hale; Herman Waldmann, 5,545,403 8/1996 Page ..................................... 424/133.1 both of University of Cambridge, 5,545.404 8/1996 Page et al. ... 424/133.1 Department of Pathology, Immunology 5,545,405 8/1996 Page ..................................... 424/133.1 Div., Tennis Court Road, Cambridge, FOREIGN PATENT DOCUMENTS CB210P, United Kingdom O3284.04 8/1989 European Pat. Off.. 21 Appl. No.: 08/244,316 3284.04 8/1989 European Pat. Off. ... A61K 39/395 22 PCT Filed: Dec. 4, 1992 OTHER PUBLICATIONS 86 PCT No.: PCT/GB92/02252 Riechmann et al., “Reshaping human antibodies for therapy”, Nature 322:323-327 (1988). S371 Date: Jun. 22, 1994 Page et al., “High Level Expression of the Humanized Monoclonal Antibody Campath-1H in Chinese Hamster S 102(e) Date: Jun. 22, 1994 Ovary Cells”, Bio/Technology 9:64–68 (1991). 87 PCT Pub. No.: WO93/10817 Myers, L.W. et al., Clinical Neuropharmacology, 8(1):119-141, Feb. 1990. PCT Pub. Date:Jun. 10, 1993 Beer, S. et al, Schweiz. Med. Wschr, 121:961–969, 1991. 30 Foreign Application Priority Data Weber et al, J of Neuro. vol. 22:1-9 (1989). Dec. 4, 1991 GB United Kingdom ................... 9125768 Primary Examiner-Christopher L. Chin Attorney, Agent, or Firm Kubovcik & Kubovcik (51) Int. Cl." ................................................... A61K 39/395 57 ABSTRACT 52 U.S. Cl.
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
    US 20170172932A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub. Date: Jun. 22, 2017 (54) EARLY CANCER DETECTION AND A 6LX 39/395 (2006.01) ENHANCED IMMUNOTHERAPY A61R 4I/00 (2006.01) (52) U.S. Cl. (71) Applicant: Gholam A. Peyman, Sun City, AZ CPC .......... A61K 9/50 (2013.01); A61K 39/39558 (US) (2013.01); A61K 4I/0052 (2013.01); A61 K 48/00 (2013.01); A61K 35/17 (2013.01); A61 K (72) Inventor: sham A. Peyman, Sun City, AZ 35/15 (2013.01); A61K 2035/124 (2013.01) (21) Appl. No.: 15/143,981 (57) ABSTRACT (22) Filed: May 2, 2016 A method of therapy for a tumor or other pathology by administering a combination of thermotherapy and immu Related U.S. Application Data notherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and pre (63) Continuation-in-part of application No. 14/976,321, vents tumor recurrence, either locally or at a different site, by filed on Dec. 21, 2015. boosting the patient’s immune response both at the time or original therapy and/or for later therapy. With respect to Publication Classification gene delivery, the inventive method may be used in cancer (51) Int. Cl. therapy, but is not limited to such use; it will be appreciated A 6LX 9/50 (2006.01) that the inventive method may be used for gene delivery in A6 IK 35/5 (2006.01) general. The controlled and precise application of thermal A6 IK 4.8/00 (2006.01) energy enhances gene transfer to any cell, whether the cell A 6LX 35/7 (2006.01) is a neoplastic cell, a pre-neoplastic cell, or a normal cell.
    [Show full text]